Catalyst Pharmaceuticals, Inc. /
Eisai Co., Ltd
Catalyst Pharmaceuticals completes purchase from Eisai Co., Ltd
- Price
- $160m
- Stage
- Closed
What happened
Catalyst Pharmaceuticals, Inc. completed its purchase of U.S. rights for FYCOMPA from Eisai Co., Ltd. The transaction included an upfront payment of $160 million.
The acquisition adds a commercial-stage epilepsy medicine to Catalyst’s U.S. portfolio.
The source
Everything on this page comes from the source below.
Catalyst Pharmaceuticals completes purchase from Eisai Co., Ltd
This document is the source for the companies, stage, figure and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly